TNXP - CONSENSUS CO - Tonix Pharmaceuticals

Tonix Pharmaceuticals (TNXP) is a diversified biotech business. The price trend illustrated in this chart is based on the development of cutting-edge drugs to combat brain pathologies and infections, where the indicator stands at 44.50. The company is currently radically changing its management model to preserve capital and accelerate final drug trials. Operational flexibility is achieved by fully outsourcing production and research to third-party contractors.

The consensus forecast represents an aggregated market valuation of an asset based on the discounting of future cash flows and the expectations of the expert community. The diversified development portfolio of Tonix Pharmaceuticals (TNXP) and government funding stabilize the analysts' consensus on the share price on GURU.Markets, allowing investors to assess capital stability through the dynamics of how forecasts adapt to new clinical data.